[Enhancement of the antitumor transplantation resistance in rats by the antileukemia drug busulfan (author's transl)].
Enhancement of antitumor transplantation immunity was observed in rats by treatment with the antileukemia drug busulfan (BU) both 5 days before and 5 days after immunization with X-irradiated tumor cells. The mechanism of the enhancement induced by BU may be due to a selective elimination of the suppressor cells from the immunized host. Similar enhancement of immunity was also observed by using other anticancer drugs when only cyclophosphamide (40 mg/kg) was given before the immunization and futraful (300 mg/kg) and mitomycin c (1 mg/kg) were given offer the immunization. However, adriamycin (4 mg/kg) did not show any enhancing effects on immunity either before or after the immunization.
D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D002066:Busulfan / Q000494:pharmacology*; D003520:Cyclophosphamide / Q000494:pharmacology; D004317:Doxorubicin / Q000494:pharmacology; D005622:Friend murine leukemia virus; D007111:Immunity, Cellular / Q000187:drug effects; D007165:Immunosuppression Therapy; D007942:Leukemia, Experimental / Q000276:immunology*; D008937:Mitomycins / Q000494:pharmacology; D009368:Neoplasm Transplantation; D051381:Rats; D013268:Stimulation, Chemical
D000970:Antineoplastic Agents; D008937:Mitomycins; D004317:Doxorubicin; D003520:Cyclophosphamide; D002066:Busulfan